[{"notes_id":"1_2278","category":"5","subcategory":"2","title":"Direct oral anticoagulants","body":"Direct oral anticoagulants (DOACs) are currently used for the following indications:<br \/><ul><li>prevention of stroke in non-valvular AF. NICE stipulate that certain other risk factors should be present. These are complicated and differ between the DOACs but generally require one of the following to be present:<ul><li>prior stroke or transient ischaemic attack<\/li><li>age 75 years or older<\/li><li>hypertension<\/li><li>diabetes mellitus<\/li><li>heart failure<\/li><\/ul><\/li><li>prevention of VTE following hip\/knee surgery<\/li><li>treatment of DVT and PE<\/li><\/ul><br \/>The table below summaries some of the differences between the DOACs:<br \/><br \/><div class=\"table-responsive\"><table class = \"tlarge table table-striped table-bordered\"  data-role=\"table\" id=\"tableid1\" ><thead><tr><th><\/th><th>Dabigatran<\/th><th>Rivaroxaban<\/th><th>Apixaban<\/th><th>Edoxaban<\/th><\/tr><\/thead><tbody><tr><td><b>Mechanism of action<\/b><\/td><td><span class=\"concept\" data-cid=\"2625\">Direct thrombin inhibitor<\/span><\/td><td><span class=\"concept\" data-cid=\"2624\">Direct factor Xa inhibitor<\/span><\/td><td><span class=\"concept\" data-cid=\"2623\">Direct factor Xa inhibitor<\/span><\/td><td>Direct factor Xa inhibitor<\/td><\/tr><tr><td><b>Excretion<\/b><\/td><td>Majority renal<\/td><td>Majority liver<\/td><td><span class=\"concept\" data-cid=\"4832\">Majority faecal<\/span><\/td><td>Majority faecal<\/td><\/tr><tr><td><b>Reversal<\/b><\/td><td><span class=\"concept\" data-cid=\"5275\">Idarucizumab<\/span><\/td><td><span class=\"concept\" data-cid=\"11094\">Andexanet alfa*<\/span><\/td><td><span class=\"concept\" data-cid=\"11094\">Andexanet alfa*<\/span><\/td><td>No authorised reversal agent, although andexanet alfa has been studied<\/td><\/tr><\/tbody><\/table><\/div><br \/>*Andexanet alfa is a recombinant form of human factor Xa protein","notes_hash":"20e149aa49c0b66620edd2bd8bbc1d65","knowledge_graph_node_id_link":0,"links":"<table style='width:100%'><tr><td>NICE<\/td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"link_like_452\" data-linkid=\"452\" data-rating=\"1\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"\/><\/svg><\/button><span id=\"link_good_count_452\" class = \"link_good_count\" style=\"color:green; font-size:85%;\">4<\/span><button type=\"button\" style=\"\" id=\"link_dislike_452\" data-linkid=\"452\" data-rating=\"0\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"\/><\/svg><\/button><span id=\"link_bad_count_452\" class = \"link_bad_count\" style=\"color:red; font-size:85%;\">4<\/span><\/td><\/tr><tr><td colspan=\"2\"><a target=\"_blank\" href=\"https:\/\/www.nice.org.uk\/guidance\/TA249\/chapter\/1-Guidance\">2012 Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation<\/a><\/td><\/tr><\/table>","media":"<table><tr><td colspan=\"2\"><a href=\"#\" class=\"media_link\" data-url=\"https:\/\/www.youtube.com\/embed\/eZBtQ0rDnG4\" data-description=\"Antiplatelets and anticoagulants made easy\" data-upvotes=\"3\" data-downvotes=\"0\" data-media=\"729\"><img border=\"0\" class=\"img-thumbnail\" alt=\"YouTube\" src=\"https:\/\/i1.ytimg.com\/vi\/eZBtQ0rDnG4\/mqdefault.jpg\" style=\"max-width:150px;\"><\/a><\/td><\/tr><tr ><td style=\"padding-top:10px\" colspan=\"2\"><a style=\"\" href=\"#\" class=\"media_link\" data-url=\"https:\/\/www.youtube.com\/embed\/eZBtQ0rDnG4\" data-description=\"Antiplatelets and anticoagulants made easy\" data-upvotes=\"3\" data-downvotes=\"0\" data-media=\"729\">Antiplatelets and anticoagulants made easy<\/a><\/td><\/tr><tr><td><span ><small>Speed Pharmacology - YouTube<\/small><\/span><\/td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"media_like_1271\" data-mediaid=\"1271\" data-rating=\"1\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"\/><\/svg><\/button><span id=\"media_good_count_1271\" class = \"media_good_count\" style=\"color:green; font-size:85%;\">3<\/span><button type=\"button\" style=\"\" id=\"media_dislike_1271\" data-mediaid=\"1271\" data-rating=\"0\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"\/><\/svg><\/button><span id=\"media_bad_count_1271\" class = \"media_bad_count\" style=\"color:red; font-size:85%;\">0<\/span><\/td><\/tr><tr><td>&nbsp;<\/td><\/tr><tr><td colspan=\"2\"><a href=\"#\" class=\"media_link\" data-url=\"https:\/\/www.youtube.com\/embed\/ys8fMaqfq4Q\" data-description=\"Haemostasis 3 - Anticoagulants & Thrombolytics\" data-upvotes=\"0\" data-downvotes=\"0\" data-media=\"164\"><img border=\"0\" class=\"img-thumbnail\" alt=\"YouTube\" src=\"https:\/\/i1.ytimg.com\/vi\/ys8fMaqfq4Q\/mqdefault.jpg\" style=\"max-width:150px;\"><\/a><\/td><\/tr><tr ><td style=\"padding-top:10px\" colspan=\"2\"><a style=\"\" href=\"#\" class=\"media_link\" data-url=\"https:\/\/www.youtube.com\/embed\/ys8fMaqfq4Q\" data-description=\"Haemostasis 3 - Anticoagulants & Thrombolytics\" data-upvotes=\"0\" data-downvotes=\"0\" data-media=\"164\">Haemostasis 3 - Anticoagulants & Thrombolytics<\/a><\/td><\/tr><tr><td><span ><small>Handwritten Tutorials - YouTube<\/small><\/span><\/td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"media_like_281\" data-mediaid=\"281\" data-rating=\"1\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"\/><\/svg><\/button><span id=\"media_good_count_281\" class = \"media_good_count\" style=\"color:green; font-size:85%;\">0<\/span><button type=\"button\" style=\"\" id=\"media_dislike_281\" data-mediaid=\"281\" data-rating=\"0\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"\/><\/svg><\/button><span id=\"media_bad_count_281\" class = \"media_bad_count\" style=\"color:red; font-size:85%;\">0<\/span><\/td><\/tr><\/table>","concepts_for_notes":{"5275":{"concept_text":"Idarucizumab is a reversal agent for dabigatran ","concept_percentile":"66"}},"category_name":"Infectious disease \/ Haematology \/ Immunology","subcategory_name":"Haematology","comment_count":2},"",[]]